RK-1355A and B, novel quinomycin derivatives isolated from a microbial metabolites fraction library based on NPPlot screening.
Two novel quinomycin derivatives, RK-1355A (1) and B (2), and one known quinomycin derivative, UK-63,598 (3), were isolated from a microbial metabolites fraction library of Streptomyces sp. RK88-1355 based on Natural Products Plot screening. The structural elucidation of 1 and 2 was established through two-dimensional NMR and mass spectrometric measurements. They belong to a class of quinomycin antibiotics family having 3-hydroxyquinaldic acid and a sulfoxide moiety. They are the first examples for natural products as a quinoline type quinomycin having a sulfoxide on the intramolecular cross-linkage. They showed potent antiproliferative activities against various cancer cell lines and they were also found to exhibit moderate antibacterial activity.
1] Antibiotics Laboratory, RIKEN, Saitama, Japan [2] Industrial Biotechnology Research Laboratory, School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Chung Liang
CL
Lim
RIKEN Center for Sustainable Research Science, Saitama, Japan.
Toshihiko
T
Nogawa
Antibiotics Laboratory, RIKEN, Saitama, Japan.
Masakazu
M
Uramoto
RIKEN Center for Sustainable Research Science, Saitama, Japan.
Akiko
A
Okano
RIKEN Global Research Cluster, Saitama, Japan.
Yayoi
Y
Hongo
RIKEN Global Research Cluster, Saitama, Japan.
Takemichi
T
Nakamura
RIKEN Global Research Cluster, Saitama, Japan.
Hiroyuki
H
Koshino
1] Antibiotics Laboratory, RIKEN, Saitama, Japan [2] RIKEN Center for Sustainable Research Science, Saitama, Japan.
Shunji
S
Takahashi
Industrial Biotechnology Research Laboratory, School of Biological Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Darah
D
Ibrahim
1] Antibiotics Laboratory, RIKEN, Saitama, Japan [2] RIKEN Center for Sustainable Research Science, Saitama, Japan.
Hiroyuki
H
Osada
D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000737:chemistry / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D055808:Drug Discovery; D004448:Echinomycin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology; D004926:Escherichia coli / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D020128:Inhibitory Concentration 50; D051379:Mice; D008826:Microbial Sensitivity Tests; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy*; D054852:Small Molecule Libraries; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D013302:Streptomyces / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; C000588822:RK-1355A; D054852:Small Molecule Libraries; C059306:UK 63598; D004448:Echinomycin